Aluminum foil for cold forming of freeze-dried pharmaceuticals is critical for packaging biological agents and antibiotics. It must meet three non-negotiable performance standards.
Primu, repeated bending toughness: It needs to withstand ≥50 cycles (disegnu prufondu, pieghendu, Sigillante) without cracks. Sicondu, impurity safety: Heavy metals must comply with Guidelines for Compatibility of Pharmaceutical Packaging Materials and Drugs. Third, prestazione di barriera: Oxygen transmission ≤0.1cm³/(m²·24h·atm) and water vapor transmission ≤0.1g/(m²·24h) to protect drugs.
To address these needs, 8079 lega (Al-Mn, Mn 0.8%-1.2%) is preferred. Its low yield strength (≤110MPa) and high elongation (≥30%) match cold forming demands for pharmaceutical packaging.
Tuttavia, 28% of brittle fractures come from two issues: excessive silicon (>0.15%) è uncontrolled melting impurities (Fe, Cu, Mg forming brittle phases).
Per esempiu, 2024 data shows a pharmacy had 12% rejected freeze-dried vaccine packaging. The cause was 8079 foil brittle fracture during cold forming, leading to an 8 million yuan single-batch loss.
Thus, clarifying why silicon must be ≤0.15% and building a melting impurity control system are urgent to ensure foil reliability.
Fundamentally, the foil’s bending performance (Gb / t 31985-2015: ≥50 180° cycles) depends on “dislocation slip ability,” which silicon directly impacts.
Silicon has dual effects: it strengthens via solid solution but can cause embrittlement. Pure aluminum dissolves up to 1.65% silicon at 25℃, but Mn in 8079 alloy reduces this solubility.
Specificamente, when Si >0.15%, excess silicon reacts with Al and Fe to form β-AlFeSi brittle phases (1-3μm, HV 280-320). These rigid structures break the matrix’s ductility.
β-AlFeSi phases are acicular or flaky. When distributed at grain boundaries, they act as “micro-cracks” that disrupt continuity.
During bending, stress concentrates at phase tips. Per esempiu, Si=0.2% hinders dislocation slip: elongation drops from 32% à 22%, and bending cycles fall from 55 à 28 (Table 1).
Di cunsiguenza, it fails to meet the strict requirements of aluminum foil for cold forming of freeze-dried pharmaceuticals.
To quantify silicon’s impact, a controlled experiment was designed.
Test samples were 0.08mm-thick 8079 foil for cold-formed pharmaceutical trays. Other elements (Fe ≤0.5%, Cu ≤0.1%, Mg ≤0.05%) were fixed; only silicon was adjusted.
Mechanical properties and bending life were tested via standard methods. After tests, results are summarized in Table 1:
1: Only Si ≤0.15% ensures ≥50 bending cycles, meeting cold forming needs.
2: Si ≤0.15% limits brittle fracture rate to ≤3%, critical for high production yields.
3: Si ≤0.15% keeps β-AlFeSi phases ≤2.1%, preserving matrix ductility.
All thresholds meet the demands of aluminum foil for cold forming of freeze-dried pharmaceuticals.
The foil’s melting has two goals: stable Si ≤0.15% and total impurities (Fe+Cu+Mg+Zn) ≤0.7% (no coarse brittle phases).
The process has four sequential stages, each building on the last. Below is a detailed breakdown:
Preventing contamination at the source is more effective than removing it later. Thus, raw material management is key.
High-purity aluminum ingots: Use ≥99.85% purity (Si ≤0.10%, Fe ≤0.15%) to align with pharmaceutical standards.
Recycled aluminum must be avoided. Its Si (0.3%-0.5%) far exceeds limits, making post-melting purification hard.
In più, precise Mn agent proportioning: Use Al-Mn master alloy (Mn 10%-15%, Si ≤0.08%) to adjust Mn content.
Per 1.0% target Mn, add 10kg master alloy per 100kg pure aluminum. This avoids excessive Mn reacting with silicon to form brittle phases.
Equally, auxiliary material purification: Melting covering agent (Na₃AlF₆-K₃AlF₆, 560-580℃ melting point) must be dried at 120℃ for 4h.
This removes adsorbed SiO₂, preventing excessive silicon in aluminum foil for cold forming of freeze-dried pharmaceuticals.
Once raw material pretreatment is complete, melting begins—temperature control is key to preventing silicon from furnace linings.
Furnace linings are high-alumina bricks (含 SiO₂), which dissolve into the melt above 720℃, increasing silicon sharply.
To prevent this, a “stepwise heating” regime is used. Detailed parameters are in Table 2:
Charging stage: 450-500℃ for 30-40min softens ingots slowly, reducing air and impurities.
Low-temperature melting: 680-720℃ for 60-80min is critical. Above 720℃, SiO₂ dissolution spikes, causing irreversible silicon overload.
Composition adjustment: 730-750℃ for 20-30min ensures uniform Mn dissolution. Overheating here accelerates silicon migration.
Standing stage: 720-730℃ for 15-20min reduces convection, avoiding uneven silicon (brittle in some areas, ductile in others).
Inolescente, real-time silicon monitoring: Take samples every 30min, test via direct-reading spectrometer (0.001% accuracy).
If Si nears 0.14%, add pure aluminum (Si ≤0.10%) to dilute. This keeps final Si of aluminum foil for cold forming of freeze-dried pharmaceuticals at 0.12%-0.15%.
Following temperature control, refining removes residual silicon and impurities that cause brittle fractures.
Primu, gas refining: Use N₂-Cl₂ mixed gas (9:1, ≥99.999% purity). Insert a graphite nozzle 150-200mm deep into the melt.
Flow rate: 0.5-0.8m³/(t·min); duration:15-20min. Nitrogen removes hydrogen (≤0.15mL/100gAl), avoiding porosity in the final foil.
Chlorine reacts with Fe/Cu to form volatile FeCl₃/CuCl₂, reducing Fe from 0.3% à 0.18% and Cu from 0.08% à 0.03%.
This avoids impurity-induced bending toughness loss.
Sicondu, flux refining: After gas refining, add 2%-3% Na₂CO₃-K₂CO₃ flux (1:1 mass ratio) to target residual silicides.
Stir for 10min, then stand for 20min. Flux reacts with silicides to form Na₂SiO₃, which floats with slag and is removed.
This further reduces Si by 0.02%-0.03%, moving it closer to 0.12%-0.15%.
Third, filtration purification: With chemical refining done, pass the melt through double-layer ceramic filters (upper 50μm, lower 20μm).
Control flow rate at 0.5-0.8m/min to avoid turbulence. Filters remove ≥20μm β-AlFeSi phases with ≥95% efficiency.
This ensures microstructural uniformity critical for aluminum foil for cold forming of freeze-dried pharmaceuticals.
With refining finished, casting and homogenization optimize the ingot’s microstructure for rolling, ensuring ductility.
Semi-continuous casting: Control parameters for fine grains (key for bending performance).
Casting temperature:710-720℃ (fluid enough to fill molds, no grain coarsening). Mold water temperature:25-30℃ (uniform cooling).
Cooling intensity:1500-2000c/(m²·K) (rapid solidification for fine grains). Casting speed:60-80mm/min (balances efficiency and quality).
These parameters yield ingots with 50-80μm grains. Fine grains reduce brittle phase concentration at boundaries, enhancing toughness.
Homogenization treatment: Heat cast ingots at 580-600℃ for 8-10h (below melting point, drives phase changes).
Cool with the furnace to 300℃ (avoid thermal shock), then air-cool to room temperature.
This converts residual β-AlFeSi to more stable α-AlFeSi (HV 220-240, better toughness). Elongation increases by 3%-5%, meeting pharmaceutical cold forming needs.
To fully validate the optimized melting process, rigorous laboratory tests were conducted.
Test samples:0.08mm-thick 8079 fogliu, specifically aluminum foil for cold forming of freeze-dried pharmaceuticals made via the above process.
Tests covered six metrics: Si content, Fe impurities, allungamentu, bending cycles, brittle fracture rate, and oxygen transmission. All followed standards like YBB00152002-2015.
Results are in Table 3, confirming compliance with pharmaceutical requirements:
1: Si=0.13% (within ≤0.15%), confirming stable control.
2: Elongation=30.5% (>28%), leading to 56 bending cycles (60% more than pre-optimization).
3: Brittle fracture rate=2.1% (<5%), ensuring high production yields.
4: Oxygen transmission=0.08cm³/(m²·24h·atm) (<0.1%), protecting drugs from oxidation.
For real-world impact, consider a major vaccine enterprise that faced 2023 production issues.
Background: The enterprise used 8079 foil with Si=0.19% for vaccine packaging.
During cold forming, brittle fracture rate reached 11.2%, rejecting 500,000+ packages and causing delays.
Faced with this issue, the enterprise incurred high rework costs and missed deadlines, needing urgent upgrades.
Process adjustments: To fix this, it adopted the optimized process to make aluminum foil for cold forming of freeze-dried pharmaceuticals.
Primu, replace low-purity ingots with 99.85% pure ones (reduced initial silicon).
Sicondu, use 720℃ low-temperature melting (prevented silicon from linings).
Third, implement N₂-Cl₂ refining (reduced Fe/Cu to non-brittle levels).
These adjustments stabilized final Si at 0.12%-0.14%.
Performance effects: As a direct result, bending cycles rose from 32 à 55 (meeting ≥50).
Brittle fracture rate dropped from 11.2% à 1.8%, cutting costs and eliminating delays.
Financially, annual losses fell by 6 million yuan, recovering upgrade costs in 6 mesi.
Compliance validation: The enterprise submitted the foil for regulatory inspection.
I risultati: Heavy metals (Pb ≤0.001%, Cd ≤0.0005%) met standards. It complied with YBB00152002-2015.
Vaccine compatibility tests showed no harmful leaching, ensuring patient safety.
These results confirmed it met aluminum foil for cold forming of freeze-dried pharmaceuticals esigenze.
Summarizing the key findings: 8079 lega foglia d'aluminiu for cold forming of freeze-dried pharmaceuticals must have Si ≤0.15%.
È >0.15% forms β-AlFeSi brittle phases, reducing elongation and bending life—making it unsuitable for cold forming.
Via the integrated process (“high-purity raw materials – low-temperature melting – composite refining – fine-grained casting”), three goals are met:
Looking ahead, three innovations will improve performance, Sostenibilità, and applicability:
Primu, intelligent melting systems: Integrate AI visual recognition and real-time spectral analysis.
AI monitors slag silicon in real time; spectral analysis adjusts Si by adding pure aluminum automatically.
This closed-loop control reduces human error, improving foil quality stability.
Sicondu, green refining: Replace chlorine with eco-friendly agents (p.e., Al₂O₃-CaO-MgO).
These remove Fe/Cu without toxic chlorine, aligning with pharmaceutical green production trends.
Third, alloy micro-alloying: Add 0.02%-0.03% Ti to refine grains to 30-50μm (smaller than current 50-80μm).
Finer grains enhance toughness and barriers, expanding use to ultra-thin foils (p.e., single-dose drug packaging).
Above all, the melting process must “prioritize pharmaceutical safety and formability” at every step.
Only with precise silicon/impurity control and ductile microstructure optimization can freeze-dried drug stability be guaranteed.
This guarantee extends across the drug lifecycle (imballaggio, U trasportu, almacenamiento, use).
This principle remains the core technical standard for producing aluminum foil for cold forming of freeze-dried pharmaceuticals and will guide future innovations.
